Weather Gauge Advisory LLC cut its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,836 shares of the pharmaceutical company’s stock after selling 638 shares during the period. Weather Gauge Advisory LLC’s holdings in GlaxoSmithKline were worth $238,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. GPM Growth Investors Inc. purchased a new position in GlaxoSmithKline in the 2nd quarter worth about $212,000. Icon Wealth Partners LLC grew its stake in shares of GlaxoSmithKline by 131.8% in the second quarter. Icon Wealth Partners LLC now owns 23,233 shares of the pharmaceutical company’s stock worth $948,000 after acquiring an additional 13,210 shares during the period. Polaris Greystone Financial Group LLC bought a new stake in shares of GlaxoSmithKline in the second quarter worth approximately $3,038,000. Manchester Financial Inc. raised its holdings in shares of GlaxoSmithKline by 382.4% during the second quarter. Manchester Financial Inc. now owns 820 shares of the pharmaceutical company’s stock valued at $33,000 after purchasing an additional 650 shares during the last quarter. Finally, Guardian Investment Management lifted its position in GlaxoSmithKline by 15.7% during the second quarter. Guardian Investment Management now owns 37,550 shares of the pharmaceutical company’s stock valued at $1,532,000 after purchasing an additional 5,100 shares during the period. Institutional investors own 12.41% of the company’s stock.
A number of brokerages have weighed in on GSK. Barclays reiterated an “underweight” rating on shares of GlaxoSmithKline in a research note on Thursday, April 30th. UBS Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research report on Thursday, May 14th. ValuEngine cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, May 5th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. GlaxoSmithKline currently has an average rating of “Hold”.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, April 29th. The pharmaceutical company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.79 by $0.18. GlaxoSmithKline had a return on equity of 43.97% and a net margin of 15.28%. The business had revenue of $11.64 billion during the quarter, compared to analyst estimates of $10.95 billion. Research analysts expect that GlaxoSmithKline plc will post 2.9 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Thursday, July 9th. Investors of record on Friday, May 15th were issued a $0.472 dividend. This represents a $1.89 annualized dividend and a yield of 4.64%. The ex-dividend date was Thursday, May 14th. GlaxoSmithKline’s dividend payout ratio is 58.99%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
See Also: What is Green Investing?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.